Are the Direct Oral Anticoagulants Better for Patients with Low Time in the Therapeutic Range on Vitamin K Antagonist Therapy?

Jordan K. Schaefer; Geoffrey D. Barnes

doi:10.1055/s-0044-1787299

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2024; 124(08): 791-794
DOI: 10.1055/s-0044-1787299

Invited Editorial Focus

Are the Direct Oral Anticoagulants Better for Patients with Low Time in the Therapeutic Range on Vitamin K Antagonist Therapy?

Autor*innen

Jordan K. Schaefer

¹Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States
Geoffrey D. Barnes

²Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States

Abstract

Volltext

Referenzen

References
1 Joglar JA, Chung MK, Armbruster AL. et al; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2024; 149 (01) e1-e156
2 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
3 Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?. J Thromb Haemost 2013; 11 (02) 390-394
4 Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353 (05) 487-497
5 Pundi KN, Perino AC, Fan J. et al. Direct oral anticoagulant adherence of patients with atrial fibrillation transitioned from warfarin. J Am Heart Assoc 2021; 10 (23) e020904
6 Toorop MMA, Chen Q, Kruip MJHA. et al. Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: does low time in therapeutic range affect persistence?. J Thromb Haemost 2022; 20 (02) 339-352
7 Solla-Ruiz I, Villanueva-Benito I, Paredes-Galán E. et al. Differences between patient-driven adherence to vitamin K antagonists and direct oral anticoagulants. Do few missed doses matter? ACO-MEMS Study. Thromb Res 2019; 179: 20-27
8 Bartoli-Abdou JK, Patel JP, Vadher B. et al. Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: findings from the Switching Study. Thromb Res 2021; 208: 162-169
9 Elling T, Hak E, Bos JH, Tichelaar VYIG, Veeger NJGM, Meijer K. Effect of previous INR control during VKA therapy on subsequent DOAC adherence and persistence, in patients switched from VKA to DOAC. Thromb Haemost 2024; 124 (08) 778-790
10 van der Horst SFB, de Vries TAC, Chu G. et al. Prevalence and predictors of nonadherence to direct oral anticoagulant treatment in patients with atrial fibrillation. TH Open 2023; 7 (03) e270-e279
11 Ozaki AF, Choi AS, Le QT. et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2020; 13 (03) e005969
12 Tarn DM, Shih KJ, Schwartz JB. Reasons for nonadherence to the direct oral anticoagulant apixaban for atrial fibrillation. J Am Geriatr Soc 2021; 69 (12) 3683-3687
13 Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. Pharmacotherapy 2017; 37 (02) 236-248
14 Charlton A, Vidal X, Sabaté M, Bailarín E, Martínez LML, Ibáñez L. Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2021; 27 (09) 1210-1220
15 Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 187-205
16 Sylvester KW, Ting C, Lewin A. et al. Expanding anticoagulation management services to include direct oral anticoagulants. J Thromb Thrombolysis 2018; 45 (02) 274-280
17 Gateman D, Trojnar ME, Agarwal G. Time in therapeutic range: warfarin anticoagulation for atrial fibrillation in a community-based practice. Can Fam Physician 2017; 63 (10) e425-e431
18 Schaefer JK, Elshoury A, Nachar VR, Streiff MB, Lim MY. How to choose an appropriate anticoagulant for cancer-associated thrombosis. J Natl Compr Canc Netw 2021; 19 (10) 1203-1210
19 McHorney CA, Crivera C, Laliberté F, Germain G, Wynant W, Lefebvre P. Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: analysis of overall population and subgroups of prior oral anticoagulant users. PLoS One 2018; 13 (04) e0194099
20 Ingason AB, Hreinsson JP, Lund SH. et al. Comparison of medication adherence to different oral anticoagulants: population-based cohort study. BMJ Open 2023; 13 (01) e065700
21 Schaefer JK, Sood SL, Haymart B. et al. Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. Blood Adv 2017; 1 (26) 2536-2540
22 Tarn DM, Shih K, Tseng C-h, Thomas A, Schwartz JB. Reasons for nonadherence to the direct oral anticoagulant apixaban. JACC Adv 2023; 2 (01) 100175
23 Chao TF, Joung B, Takahashi Y. et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thromb Haemost 2022; 122 (01) 20-47
24 Treewaree S, Lip GYH, Krittayaphong R. Non-vitamin K antagonist oral anticoagulant, warfarin, and ABC pathway adherence on hierarchical outcomes: win ratio analysis of the COOL-AF registry. Thromb Haemost 2024; 124 (01) 69-79
25 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the ‘Atrial Fibrillation Better Care’ pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414